secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001437749-25-027256
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma raises $6.5M, Q2 operating loss improves to $3.7M, FDA expands Fast Track for NRX-100
--------------------------------------------------------------------------------

- Registered direct offering of 3,959,999 shares at $1.65/sh raises ~$6.5M; one-year lockup, no warrants.
- Q2 net loss $17.6M (vs $7.9M) on non-cash fair value changes; operating loss narrows to $3.7M (vs $7.1M).
- FDA expanded Fast Track for NRX-100 to all depression types, addressing 13M Americans annually.
- Cash balance $2.9M at June 30; with new capital expects to fund operations into 2026.
- HOPE Therapeutics acquires Dura Medical, signs LOIs for NeuroSpa and Cohen and Associates; debt financing $7.8M approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925027256/0001437749-25-027256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925027256/nrxp20250818_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer